December 23, 2020
20 min listen
Save
Dr. Mali’s Top 5 Predictions in Ophthalmology for 2021
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this special episode, I sit down with this week’s co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show.
- Intro :14
- In this episode :21
- About Yasmin P. Mali, MD :35
- Dr. Mali’s first prediction: The human spirit and innovation will triumph over the headline-dominating COVID-19 1:16
- Dr. Yasmin Mali’s thoughts on the first predictions 2:58
- Dr. Mali’s second prediction: The competition battle lines will be drawn for ocular therapeutics in the most common eye disease markets 4:04
- Thoughts on the potential products in 2021 6:25
- Dr. Mali’s third prediction: Increased use of artificial intelligence in clinical ophthalmology 8:18
- Any advances in artificial intelligence for pediatric ophthalmology? 10:15
- Dr. Mali’s fourth prediction: Telemedicine platforms will still play a role in ophthalmology 11:24
- Thoughts on telemedicine in the pediatric ophthalmology community 13:44
- Dr. Mali’s fifth prediction: Virtual ophthalmology conference options will remain present for the majority of 2021 15:17
- Dr. Mali’s thoughts on the virtual meetings attended in 2020 17:10
- Dr. Mali’s bonus announcement 18:34
- Dr. Yasmin Mali’s final words 18:48
Yasmin P. Mali, MD, is a board-certified ophthalmologist and fellowship trained pediatric ophthalmologist. Mali is currently faculty at Lake Erie College of Osteopathic Medicine in Bradenton, Florida.
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Yasmin Mali, MD, reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
